27
total announcements
543904.BO · 15 min delayed
Mankind Pharma Ltd
Mankind Pharma Ltd has allotted 49,112 equity shares to eligible employees under the Mankind Employee Stock Option Plan 2022, increasing the paid-up share capital from 41,29,95,978 to 41,30,45,090 equity shares.
Mankind Pharma Ltd
Mankind Pharma Ltd has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP and its Partners, effective August 31, 2026.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the completion of the term of Independent Director Mr. Bharat Anand, effective August 30, 2026. He has ceased to be a member of the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the outcome of its Board Meeting, where it has approved the integration of Bharat Serums and Vaccines Limited (BSVL) with the Company through voluntary liquidation. The business of BSVL will be distributed to Mankind Pharma on a going concern basis, and Appian, a wholly-owned subsidiary of the Company, will receive cash proportionate to its shareholding.
Mankind Pharma Ltd
Mankind Pharma Ltd's Board of Directors has approved the integration of Bharat Serums and Vaccines Limited (BSVL) with the company through a voluntary liquidation process. The Company holds 96% shares of BSVL, and Appian Properties Private Limited, a wholly-owned subsidiary, holds 4%. The business of BSVL will be distributed to the Company on a going concern basis, and Appian will receive cash proportionate to its shareholding.
Mankind Pharma Ltd
Mankind Pharma Ltd has received an ESG Rating of 64 from CRISIL ESG Ratings, classified as 'Strong', representing an improvement from the previous rating of 57. The Company's Core ESG Rating has also improved to 71 from 60.
Mankind Pharma Ltd
Mankind Pharma Ltd has entered into an exclusive in-licensing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. for the commercialization of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India. This partnership further strengthens Mankind Pharma's presence in the diabetes segment and expands its injectable diabetes portfolio.
Mankind Pharma Ltd
Mankind Pharma Ltd has published a newspaper advertisement confirming the dispatch of the Notice of Postal Ballot and providing other requisite information pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced a postal ballot notice for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director of the Company. The appointment is proposed for approval by the members of Mankind Pharma Ltd through remote e-voting.
Mankind Pharma Ltd
Mankind Pharma Ltd has completed the realignment of security cover for its Non-Convertible Debentures, releasing 28,280 pledged shares of Bharat Serums and Vaccines Ltd. The revised security cover is 1.26 times the outstanding NCDs.
Mankind Pharma Ltd
Mankind Pharma Ltd has incorporated a wholly owned subsidiary company in Netherlands, as per the company's earlier intimation dated July 11, 2026.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, with effect from August 10, 2026. The Board of Directors has also approved the Postal Ballot Notice for seeking approval of the members of the Company for the appointment of Mr. Bafna for a term of 5 (five) consecutive years.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, with effect from August 10, 2026. The Board of Directors has also approved the Postal Ballot Notice for seeking approval of the members of the Company for the appointment of Mr. Bafna for a term of 5 (five) consecutive years.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, with effect from August 10, 2026. The appointment is subject to approval by the members of the Company. Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector, with significant experience in managing global healthcare businesses and operations across multiple geographies.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced its participation in three investor conferences scheduled to take place in Mumbai between August 13 and 17, 2026. The company's management officials will engage in one-on-one and group meetings with investors and analysts, discussing the general business outlook and information already in the public domain. The company has assured that no unpublished price-sensitive information will be disclosed during these meetings.
Mankind Pharma Ltd
Mankind Pharma Ltd held its 35th AGM on August 4, 2026, through video conferencing. The voting results and scrutinizer's report are attached. All resolutions were approved with the requisite majority.
Mankind Pharma Ltd
Mankind Pharma Ltd held its 35th Annual General Meeting (AGM) on August 4, 2026, through video conferencing. The meeting was attended by 143 members, and the requisite quorum was present. The proceedings were conducted smoothly, and the members were provided with an opportunity to participate and vote on the items being considered in the AGM.
Mankind Pharma Ltd
Mankind Pharma Ltd's Q1FY27 earnings conference call transcript is available on the company's website, with overall revenue increasing to INR4,031 crores, up 13% year-on-year, and EBITDA margin improving by 250 bps year-on-year to 26.3%.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the unaudited financial results for the quarter ended June 30, 2026, as published in the newspapers 'Financial Express' and 'Jansatta' on July 31, 2026.
Mankind Pharma Ltd
Mankind Pharma Ltd has announced the availability of the audio recording of its Q1FY27 investor conference call, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.